Regional Laboratory, LLC

Regional Laboratory, LLC was paid $2.54M by Medicaid between Jan 2018 and Dec 2024, across 154 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 53% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#37 of 436

Median peer was paid$17K

This provider vs. median147×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	29,980	$22K
2019	15,912	$14K
2020	24,349	$180K
2021	114,335	$1.16M
2022	110,562	$1.06M
2023	721	$3K
2024incomplete	27,792	$96K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	53%	34,984	21,706	$1.35M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	9.2%	21,509	13,003	$234K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	7.5%	18,062	13,111	$189K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.3%	3,570	3,269	$59K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.7%	4,405	4,019	$43K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.6%	7,893	7,130	$40K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.5%	3,258	2,175	$38K
84443	Thyroid stimulating hormone (TSH)	1.4%	12,535	11,424	$37K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.4%	24,857	21,174	$36K
80053	Comprehensive metabolic panel	1.2%	19,740	16,999	$31K
80061	Lipid panel	1.2%	12,446	11,544	$30K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.1%	2,680	2,427	$28K

142 more codes

83036	Hemoglobin; glycosylated (A1C)	1.1%	12,242	$27K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.0%	1,389	$25K
80050	General health panel	<1%	1,638	$23K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,245	$18K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	616	$17K
82728		<1%	3,964	$16K
82607		<1%	4,763	$15K
84481		<1%	2,952	$15K
84702		<1%	2,322	$13K
87631		<1%	1,282	$12K
87340		<1%	3,251	$12K
86803		<1%	2,397	$12K
86696		<1%	1,514	$11K
84439		<1%	4,855	$11K
84466		<1%	3,570	$11K
86762		<1%	1,601	$10K
87481		<1%	2,273	$9K
86695		<1%	1,531	$8K
82746		<1%	2,326	$7K
86592		<1%	4,008	$7K
84144		<1%	1,130	$7K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	891	$7K
83540		<1%	3,685	$6K
87653		<1%	1,756	$5K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	204	$5K
87640		<1%	1,188	$5K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	276	$5K
87551		<1%	1,285	$4K
87556		<1%	1,642	$4K
87486		<1%	1,467	$4K
87581		<1%	1,467	$4K
86780		<1%	890	$4K
87529		<1%	483	$3K
84403		<1%	513	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,427	$3K
83970		<1%	599	$3K
87561		<1%	1,284	$3K
87532		<1%	1,264	$3K
87498		<1%	1,265	$3K
87541		<1%	1,265	$3K
87496		<1%	1,696	$3K
87500		<1%	1,108	$3K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,605	$2K
87641		<1%	1,064	$2K
84153		<1%	716	$2K
87511		<1%	387	$2K
84550		<1%	1,791	$2K
81001		<1%	4,006	$2K
85651		<1%	2,442	$2K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	88	$2K
83735		<1%	1,624	$2K
82950		<1%	989	$2K
88142		<1%	99	$2K
82670		<1%	197	$2K
86769		<1%	56	$2K
85610		<1%	1,723	$2K
85027		<1%	861	$1K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	191	$1K
83001		<1%	196	$1K
85730		<1%	466	$1K
84436		<1%	1,104	$997.31
86704		<1%	283	$986.24
85045		<1%	1,060	$952.99
84146		<1%	177	$937.33
83002		<1%	159	$933.94
86703		<1%	77	$930.02
82784		<1%	284	$925.65
86708		<1%	291	$917.48
86038		<1%	319	$799.16
86140		<1%	784	$770.07
82043		<1%	779	$768.36
84134		<1%	326	$652.70
84100		<1%	715	$641.06
82570		<1%	831	$603.99
84479		<1%	705	$562.53
83880		<1%	411	$561.76
86431		<1%	478	$542.79
84270		<1%	132	$531.53
82378		<1%	133	$519.89
83615		<1%	293	$502.97
86709		<1%	170	$498.20
87150		<1%	41	$389.88
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	66	$372.98
80048	Basic metabolic panel (calcium, ionized)	<1%	1,478	$336.32
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	56	$333.88
85384		<1%	40	$248.14
82248		<1%	377	$237.27
82977		<1%	117	$201.42
86304		<1%	63	$197.27
83690		<1%	144	$185.10
86706		<1%	79	$183.69
86160		<1%	57	$174.60
86301		<1%	58	$167.44
80164		<1%	421	$150.61
87186		<1%	360	$136.81
G0476	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test	<1%	14	$135.20
87077		<1%	355	$135.17
87088		<1%	458	$120.57
82947		<1%	118	$114.34
86235		<1%	30	$108.81
86225		<1%	29	$106.76
87563		<1%	194	$89.21
82550		<1%	111	$88.96
85048		<1%	2,352	$82.97
87799		<1%	25	$79.96
87081		<1%	41	$73.76
80076		<1%	260	$73.32
82232		<1%	27	$67.12
86885		<1%	12	$65.90
86300		<1%	50	$65.36
86800		<1%	12	$63.44
87482		<1%	26	$46.82
83525		<1%	14	$45.96
84480		<1%	13	$44.13
84154		<1%	14	$36.41
86900		<1%	12	$34.40
86901		<1%	12	$34.40
84484		<1%	26	$33.02
82553		<1%	25	$26.08
87205		<1%	12	$21.02
36415	Collection of venous blood by venipuncture	<1%	22,070	$14.76
84156		<1%	31	$12.80
80069		<1%	210	$10.95
85008		<1%	226	$5.76
86308		<1%	12	$5.37
85007		<1%	32	$3.56
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	819	$0.00
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	0%	13	$0.00
83721		0%	47	$0.00
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	0%	39	$0.00
84155		0%	18	$0.00
85014		0%	19	$0.00
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	0%	6,289	$0.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	5,481	$0.00
82040		0%	15	$0.00
84075		0%	29	$0.00
80177		0%	87	$0.00
82952		0%	34	$0.00
86060		0%	12	$0.00
80185		0%	60	$0.00
G0103	Prostate cancer screening; prostate specific antigen test (psa)	0%	14	$0.00
85018		0%	20	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGIETZ, JAMES (PRESIDENT)